Novobiocin inhibits RNA polymerase III transcription in vitro by a mechanism distinct from DNA topoisomerase II.
The role of DNA topoisomerases in eucaryotic class III gene transcription in vitro has been studied through the use of inhibitory drugs and antisera to DNA topoisomerases I and II. The DNA topoisomerase II inhibitors, novobiocin and coumermycin AI, were found to inhibit transcription of cloned 5S and tRNA genes. Novobiocin acts by interfering with an ATP-requiring step in the pathway to stable preinitiation complex formation. However, it is unlikely that this step reflects the enzymatic action of DNA topoisomerase II since a specific inhibitor of this enzyme (VM-26) and anti-DNA topoisomerase II antibodies fail to inhibit transcription under conditions where topoisomerase II enzymatic activity is inhibited. Similarly, a specific inhibitor of DNA topoisomerase I (camptothecin) and anti-DNA topoisomerase I antibodies fail to inhibit class III gene transcription. These results argue against a role for either DNA topoisomerase in 5S or tRNA gene transcription in vitro.
D049933:Aminocoumarins; D002166:Camptothecin / Q000494:pharmacology; D003374:Coumarins / Q000494:pharmacology; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors*; D006367:HeLa Cells; D009675:Novobiocin / Q000494:pharmacology*; D012320:RNA Polymerase III / Q000037:antagonists & inhibitors*; D012335:RNA, Ribosomal / Q000096:biosynthesis; D012343:RNA, Transfer / Q000096:biosynthesis; D013713:Teniposide / Q000494:pharmacology; D059005:Topoisomerase II Inhibitors; D014158:Transcription, Genetic / Q000187:drug effects*
D049933:Aminocoumarins; D003374:Coumarins; D012335:RNA, Ribosomal; D059005:Topoisomerase II Inhibitors; D009675:Novobiocin; D012343:RNA, Transfer; D013713:Teniposide; D012321:DNA-Directed RNA Polymerases; D012320:RNA Polymerase III; C004628:coumermycin; D002166:Camptothecin